Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Missouri appeals court...

    Missouri appeals court tosses 55 million dollar Johnson and Johnson talc-powder verdict

    Written by Ruby Khatun Khatun Published On 2018-07-01T10:00:58+05:30  |  Updated On 1 July 2018 10:00 AM IST
    Missouri appeals court tosses 55 million dollar Johnson and Johnson talc-powder verdict

    A Missouri appeals court threw out a $55 million verdict against Johnson and Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using talc-based products, including J&J’s baby powder, citing a U.S. Supreme court ruling on where such cases can be brought.


    South Dakota resident Gloria Ristesund had been awarded $5 million in compensatory damages and $50 million in punitive damages in the 2016 verdict.


    She alleged that her decades-long use of J&J talc-based products for feminine hygiene caused her cancer and that the company had failed to warn consumers about the risks.


    J&J denied the allegations, saying decades of testing have shown its cosmetic talc-based products to be safe.


    The healthcare conglomerate is battling some 9,000 cases claiming its talc-based products cause ovarian cancer and, in some cases, mesothelioma, rare cancer closely linked to asbestos exposure, amid allegations the products were contaminated with asbestos fibers. J&J has said its talc products do not contain asbestos or cause any form of cancer.


    The unanimous three-judge panel of the Missouri Court of Appeals in the Eastern District, in overturning the verdict, did not rule on the merits of the allegations.


    The judges instead said the verdict could not stand following a 2017 U.S. Supreme Court decision that limits where companies can be sued for personal injuries.


    The high court ruled that state courts cannot hear claims against companies that are not based in the state or when the alleged injuries did not occur there.


    J&J is based in New Jersey and Ristesund exclusively purchased and used the company’s talc products in South Dakota and Minnesota, according to court records.


    J&J, in a statement, said it was extremely pleased with the court’s decision to recognize that the trial should have never occurred.


    Ristesund’s case was one of more than 60 related talc lawsuits consolidated in Missouri state court, where juries have a reputation for issuing high-paying verdicts. But only one of those cases involved a woman from Missouri, leading many of the cases to be tossed on jurisdictional grounds.


    During the appeals process, Ristesund asked the court for permission to present additional evidence tying J&J to Missouri. The judges on Friday rejected her request, saying she had ample opportunity to present such evidence over the past two years.





    (Reporting by Tina Bellon; Editing by David Gregorio and Bill Berkrot)




    baby powdercancerfeminine hygienehealthcare conglomerateJohnson and JohnsonJohnson Baby PowderlawsuitmesotheliomaMissouriovarian cancer
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok